Merck , known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has approved new labeling for Isentress Film-coated Tablets, Merck's integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy.
http://www.drugs.com/newdrugs/fda-approves-new-u-s-labeling-isentress-raltegravir-include-240-week-results-startmrk-study-3838.html?
http://www.drugs.com/newdrugs/fda-approves-new-u-s-labeling-isentress-raltegravir-include-240-week-results-startmrk-study-3838.html?
